J Korean Neuropsychiatr Assoc.  2002 Nov;41(6):1081-1088.

One-year Follow-up of the Hospitalized Schizophrenic Patients Treated with Risperidone or Olanzapine: Aspects in Cost Economy

• Kim CE
• Kim JM
• Moon HW
• Bae JN
• Kang MH

Abstract

OBJECTIVES
This study was conducted to access the cost-effectiveness of risperidone or olanzapine in a subset of patients with schizophrenia.
METHODS
Two schizophrenia patient groups who were with risperidone(n=17) or olanzapine(n=20) were compared with each other in total medical cost, average daily cost of antipsychotics, discharge rate, drop-out rate, readmission rate and extropyramidal side effect(EPS).
RESULTS
The average daily costs of risperidone and olanzapine treated groups were \9,778 and \9,536 in admission, and \2,219 and \5,118 in patients one year after discharge respectively. Risperidone group showed higher rate of EPS than olanzapine group. There was no significant difference in discharge or drop-out rate.
CONCLUSIONS
Olanzapine group had higher total daily medical cost and daily medication cost, while risperidone group showed higher readmission and EPS rate.

Keyword

Cost-effectiveness; Direct medical cost; Risperidone; Olanzapine

MeSH Terms

Antipsychotic Agents
Follow-Up Studies*
Humans
Risperidone*
Schizophrenia
Antipsychotic Agents
Risperidone